| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1009706483 |
| P356 | DOI | 10.1038/SJ.ONC.1209785 |
| P8608 | Fatcat ID | release_zpsi6qdgtfhfnnyco6lgr3n5l4 |
| P698 | PubMed publication ID | 16819506 |
| P5875 | ResearchGate publication ID | 6964496 |
| P50 | author | Wolfgang Wick | Q2591750 |
| Wynand P Roos | Q40011092 | ||
| Carlos F. Menck | Q58336882 | ||
| P2093 | author name string | M Weller | |
| B Kaina | |||
| L F Z Batista | |||
| S C Naumann | |||
| P2860 | cites work | Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with antisera: a method for studying antibody specificity and antigen structure | Q24596350 |
| A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
| Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents | Q27777800 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Suppression of spontaneous mutagenesis in human cells by DNA base excision-repair | Q28142064 | ||
| Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product | Q28639862 | ||
| Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. | Q30454407 | ||
| Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents | Q33689518 | ||
| MGMT: its role in cancer aetiology and cancer therapeutics | Q34310201 | ||
| O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy | Q34561510 | ||
| Reduced RNA polymerase II transcription in intact and permeabilized Cockayne syndrome group B cells | Q36128504 | ||
| p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs | Q36401199 | ||
| An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. | Q36412005 | ||
| Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents | Q37939678 | ||
| Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine | Q38314205 | ||
| His1205 and His1223 are essential for the activity of the mitogenic Pasteurella multocida toxin | Q38355206 | ||
| O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells | Q40331848 | ||
| Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide | Q40522471 | ||
| Apoptotic signaling in response to a single type of DNA lesion, O(6)-methylguanine. | Q40569371 | ||
| DNA damage tolerance, mismatch repair and genome instability | Q40582064 | ||
| Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells | Q40600919 | ||
| Apoptosis induced by MNNG in human TK6 lymphoblastoid cells is p53 and Fas/CD95/Apo-1 related | Q40611968 | ||
| CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death | Q40616862 | ||
| DNA double-strand breaks trigger apoptosis in p53-deficient fibroblasts | Q40815312 | ||
| Determination of the initial DNA damage and residual DNA damage remaining after 12 hours of repair in eleven cell lines at low doses of irradiation | Q40839521 | ||
| Mismatch repair defects and O6-methylguanine-DNA methyltransferase expression in acquired resistance to methylating agents in human cells | Q41082110 | ||
| Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids | Q42560730 | ||
| The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. | Q44285539 | ||
| DNA repair protein MGMT protects against N-methyl-N-nitrosourea-induced conversion of benign into malignant tumors | Q44381272 | ||
| Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase π in glioblastoma and the survival of the patients treated with nimustine hydrochloride: An immunohistochemical analysis | Q44435562 | ||
| Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. | Q44729054 | ||
| Loss of ATM sensitizes against O6-methylguanine triggered apoptosis, SCEs and chromosomal aberrations | Q44792776 | ||
| O6-methylguanine-DNA methyltransferase activity in human tumors | Q44796645 | ||
| G2 damage checkpoints: what is the turn-on? | Q45198956 | ||
| Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents | Q46067039 | ||
| p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis | Q48195275 | ||
| Alkylation-induced apoptosis of embryonic stem cells in which the gene for DNA-repair, methyltransferase, had been disrupted by gene targeting. | Q52525643 | ||
| Removal of O6-methylguanine from DNA of normal and xeroderma pigmentosum-derived lymphoblastoid lines. | Q54256756 | ||
| O6-methylguanine-DNA methyltransferase activity in breast and brain tumors. | Q55480784 | ||
| The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase | Q70533182 | ||
| Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs | Q71058150 | ||
| Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models | Q74063639 | ||
| O6-alkylguanine DNA lesions trigger apoptosis | Q74302180 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | temozolomide | Q425088 |
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 186-197 | |
| P577 | publication date | 2006-07-03 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine | |
| P478 | volume | 26 |
| Q97526979 | A Potential Mechanism of Temozolomide Resistance in Glioma-Ferroptosis |
| Q30501296 | A chalcone-related small molecule that induces methuosis, a novel form of non-apoptotic cell death, in glioblastoma cells |
| Q52646455 | A highlight on Sonic hedgehog pathway. |
| Q30412393 | A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival |
| Q36085637 | A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT) |
| Q36455403 | A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study |
| Q34088805 | A rapid survival assay to measure drug-induced cytotoxicity and cell cycle effects |
| Q35966272 | A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy |
| Q36907370 | A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells |
| Q35088396 | A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme |
| Q34722539 | APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo |
| Q36210284 | AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin |
| Q34412530 | Activation of AMP-activated Protein Kinase by Temozolomide Contributes to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1 Inhibition |
| Q36907121 | Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach |
| Q54973470 | Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature. |
| Q36500074 | Advances in the management of glioblastoma: the role of temozolomide and MGMT testing |
| Q34241602 | Alkyltransferase-like protein (eATL) prevents mismatch repair-mediated toxicity induced by O6-alkylguanine adducts in Escherichia coli. |
| Q52730709 | Amentoflavone Induces Apoptosis and Inhibits NF-ĸB-modulated Anti-apoptotic Signaling in Glioblastoma Cells. |
| Q38261426 | Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. |
| Q39167592 | Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment |
| Q64107495 | Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? |
| Q42237770 | Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence |
| Q60935363 | Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma |
| Q37522376 | BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53. |
| Q36148612 | BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomide |
| Q49640790 | BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas |
| Q47159055 | BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway |
| Q40720470 | Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma |
| Q92727767 | Bcl2-Expressing Quiescent Type B Neural Stem Cells in the Ventricular-Subventricular Zone Are Resistant to Concurrent Temozolomide/X-Irradiation |
| Q36259173 | Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. |
| Q55456993 | Bufalin induces apoptosis and improves the sensitivity of human glioma stem-like cells to temozolamide. |
| Q35095013 | CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. |
| Q39264163 | Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin? |
| Q46547610 | Caudatin induces caspase-dependent apoptosis in human glioma cells with involvement of mitochondrial dysfunction and reactive oxygen species generation |
| Q39514906 | Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair. |
| Q38431462 | Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma. |
| Q35521316 | Chemoresistance of glioblastoma cancer stem cells--much more complex than expected |
| Q39354541 | Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma |
| Q39712685 | Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent |
| Q34037067 | Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. |
| Q39069742 | Combination treatment for glioblastoma cells with tumor necrosis factor-related apoptosis-inducing ligand and oncolytic adenovirus delta-24. |
| Q36982114 | Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model |
| Q37870216 | Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? |
| Q38066230 | Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma |
| Q39555301 | Considering temozolomide as a novel potential treatment for esophageal cancer |
| Q47984087 | Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery. |
| Q48287471 | Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model |
| Q38230650 | Current evidence of temozolomide and bevacizumab in treatment of gliomas. |
| Q33907663 | Cytotoxic autophagy in cancer therapy |
| Q39651536 | DNA Damage–Induced Modulation of GLUT3 Expression Is Mediated through p53-Independent Extracellular Signal-Regulated Kinase Signaling in HeLa Cells |
| Q28271163 | DNA damage and the balance between survival and death in cancer biology |
| Q37273862 | DNA methylation-mediated nucleosome dynamics and oncogenic Ras signaling: insights from FAS, FAS ligand and RASSF1A. |
| Q36681945 | Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells |
| Q38895190 | Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide |
| Q38739120 | Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells |
| Q90381867 | Development of an Aryloxazole Derivative as a Brain-Permeable Anti-Glioblastoma Agent |
| Q58761872 | Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells |
| Q39869690 | Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide |
| Q33386298 | Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. |
| Q38777339 | Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment |
| Q55058138 | Downregulation of Leucine-Rich Repeat-Containing 8A Limits Proliferation and Increases Sensitivity of Glioblastoma to Temozolomide and Carmustine. |
| Q91974737 | Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway |
| Q37660295 | EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma |
| Q37536711 | ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis |
| Q28487714 | Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage |
| Q39680548 | Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival. |
| Q48114950 | Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells |
| Q39305165 | Effect of temozolomide on the U-118 glioma cell line |
| Q40257600 | Effect of temozolomide on the viability of musculoskeletal sarcoma cells |
| Q39356631 | Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines |
| Q55467906 | Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. |
| Q33894470 | Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models |
| Q58554073 | Epigenetic Targeting of Glioblastoma |
| Q92628342 | Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model |
| Q64109379 | Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma |
| Q33777877 | First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response |
| Q37066677 | Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells |
| Q38868168 | Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines |
| Q60916522 | Functional Blockade of Small GTPase RAN Inhibits Glioblastoma Cell Viability |
| Q47258480 | Functional network analysis of gene-phenotype connectivity associated with temozolomide |
| Q37450330 | GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment |
| Q37027203 | Glioblastoma multiforme: the role of DSB repair between genotype and phenotype |
| Q47553080 | Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. |
| Q36291188 | Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo |
| Q47100546 | Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma |
| Q36645695 | High levels of cellular proliferation predict pseudoprogression in glioblastoma patients |
| Q38697884 | Hinokitiol suppresses cancer stemness and oncogenicity in glioma stem cells by Nrf2 regulation |
| Q41845392 | How efficient are autophagy inhibitors as treatment for glioblastoma? |
| Q33709922 | IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway |
| Q35832054 | Identification of a novel pro-apopotic function of NF-kappaB in the DNA damage response |
| Q38985855 | Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis |
| Q33613430 | Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model |
| Q36362798 | Impact of temozolomide on immune response during malignant glioma chemotherapy |
| Q39630886 | In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation. |
| Q37626600 | Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma |
| Q39368816 | Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival |
| Q36701435 | Inhibition of Na(+)-K(+)-2Cl(-) cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells |
| Q34571940 | Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program |
| Q41630032 | Integrins and p53 pathways in glioblastoma resistance to temozolomide |
| Q39908793 | Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells |
| Q34197351 | Is there a common upstream link for autophagic and apoptotic cell death in human high-grade gliomas? |
| Q30500762 | JLK1486, a Bis 8-Hydroxyquinoline-Substituted Benzylamine, Displays Cytostatic Effects in Experimental Gliomas through MyT1 and STAT1 Activation and, to a Lesser Extent, PPARγ Activation |
| Q39538477 | Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. |
| Q39474858 | Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells |
| Q64376485 | LRRC8A potentiates temozolomide sensitivity in glioma cells via activating mitochondria-dependent apoptotic pathway |
| Q38709582 | Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling |
| Q36812597 | Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection |
| Q34105361 | Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression |
| Q33588294 | Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells |
| Q49808449 | MACF1 knockdown in glioblastoma multiforme cells increases temozolomide-induced cytotoxicity |
| Q48181924 | MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance. |
| Q89622560 | MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas |
| Q46901432 | MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. |
| Q39447204 | MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis |
| Q38350366 | MMR/c-Abl-dependent activation of ING2/p73alpha signaling regulates the cell death response to N-methyl-N'-nitro-N-nitrosoguanidine |
| Q39162918 | Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair |
| Q48640997 | Mechanisms involved in kinin-induced glioma cells proliferation: the role of ERK1/2 and PI3K/Akt pathways |
| Q36545028 | Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo |
| Q39239705 | Metformin treatment reduces temozolomide resistance of glioblastoma cells |
| Q36249145 | Methylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation |
| Q40867629 | Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis |
| Q36230477 | Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O(6)-methylguanine-DNA methyltransferase expression in endothelial cells |
| Q28118866 | MiR-221/222 target the DNA methyltransferase MGMT in glioma cells |
| Q39990148 | MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. |
| Q92668988 | MicroRNA-9 enhances chemotherapy sensitivity of glioma to TMZ by suppressing TOPO II via the NF-κB signaling pathway |
| Q36088616 | Modulation of Pathways Underlying Distinct Cell Death Mechanisms in Two Human Lung Cancer Cell Lines in Response to SN1 Methylating Agents Treatment |
| Q38465854 | Molecular targets in glioblastoma |
| Q36544108 | Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets |
| Q42828839 | Mouse embryonic stem cells are hypersensitive to apoptosis triggered by the DNA damage O(6)-methylguanine due to high E2F1 regulated mismatch repair |
| Q36812820 | Multifocal atrophy of cerebellar internal granular neurons in lesch-nyhan disease: case reports and review |
| Q35056313 | N-(2-hydroxyphenyl)acetamide (NA-2) and Temozolomide synergistically induce apoptosis in human glioblastoma cell line U87. |
| Q29247923 | NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells |
| Q37261125 | New (alternative) temozolomide regimens for the treatment of glioma |
| Q36292215 | Non-coding RNAs--novel targets in neurotoxicity |
| Q36288503 | O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas |
| Q35844142 | O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies |
| Q37037194 | O6-methylguanine-induced cell death involves exonuclease 1 as well as DNA mismatch recognition in vivo |
| Q42738436 | Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis |
| Q34802264 | Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair |
| Q33931980 | Pathologies associated with the p53 response |
| Q36750717 | Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant |
| Q48024213 | Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma. |
| Q38557882 | Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics |
| Q37444920 | Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. |
| Q48127393 | Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. |
| Q47447057 | Pyrrolidine dithiocarbamate sensitizes U251 brain glioma cells to temozolomide via downregulation of MGMT and BCL-XL. |
| Q53219322 | QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells. |
| Q36971305 | Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. |
| Q33601945 | Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. |
| Q40146451 | RAD51D protects against MLH1-dependent cytotoxic responses to O(6)-methylguanine |
| Q34071842 | Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs |
| Q39060215 | Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma |
| Q48256976 | Repair gene O6 -methylguanine-DNA methyltransferase is controlled by SP1 and up-regulated by glucocorticoids, but not by temozolomide and radiation. |
| Q37580498 | Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype |
| Q28541765 | Retracted: Enhanced Anti-Tumor Effect of Zoledronic Acid Combined with Temozolomide against Human Malignant Glioma Cell Expressing O6-Methylguanine DNA Methyltransferase |
| Q89892796 | Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions |
| Q90501007 | Sequence-Specific Quantitation of Mutagenic DNA Damage via Polymerase Amplification with an Artificial Nucleotide |
| Q55332110 | Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. |
| Q34576873 | Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage |
| Q91707747 | Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists |
| Q36104739 | Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. |
| Q47815891 | Synthesis and biological evaluation of glycosides containing triazene-chalcones |
| Q39024309 | Synthesis, and In-vitro Cytotoxicity Studies of a Series of Triazene Derivatives on Human Cancer Cell Lines |
| Q44705929 | Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity |
| Q37780712 | Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy |
| Q37356520 | Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide |
| Q61800092 | Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities |
| Q28550138 | Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression |
| Q90040743 | Temozolomide and Other Alkylating Agents in Glioblastoma Therapy |
| Q37995906 | Temozolomide dosing regimens for glioma patients |
| Q39167955 | Temozolomide in combination with carbon ion or photon irradiation in glioblastoma multiforme cell lines - does scheduling matter? |
| Q79736823 | Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists |
| Q38760726 | Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy |
| Q34754083 | Temozolomide modifies caveolin-1 expression in experimental malignant gliomas in vitro and in vivo |
| Q30353110 | Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression |
| Q43188994 | Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. |
| Q99414141 | Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma |
| Q49922510 | Temozolomide-associated Hypermutation in Gliomas |
| Q43092195 | Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways |
| Q42511174 | The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity |
| Q38884854 | The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment |
| Q42659700 | The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity |
| Q38093776 | The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience |
| Q35142283 | The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation |
| Q38981224 | The interruption of PKC-ι signaling and TRAIL combination therapy against glioblastoma cells |
| Q36288254 | The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells. |
| Q90169615 | The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma |
| Q38738437 | The regrowth kinetic of the surviving population is independent of acute and chronic responses to temozolomide in glioblastoma cell lines |
| Q36485266 | The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas |
| Q39377008 | Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system |
| Q28273012 | Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents |
| Q36943893 | Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin |
| Q36651893 | Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas |
| Q35657822 | Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy |
| Q37010405 | Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy |
| Q28550980 | Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways |
| Q30572906 | WNK1-OSR1 kinase-mediated phospho-activation of Na+-K+-2Cl- cotransporter facilitates glioma migration |
| Q38987085 | mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells |
| Q39546294 | p53 promotes cellular survival in a context-dependent manner by directly inducing the expression of haeme-oxygenase-1. |
| Q42925815 | p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor |
Search more.